Avet Pharma Announces the Launch of Isosorbide Mononitrate ER 30mg Tablets

Eatontown, NJ, January, 31 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Isosorbide Mononitrate Extended-Release 30mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products, and is an addition to Avet’s marketed Isosorbide Mononitrate ER 60mg tablets. Isosorbide Mononitrate is the AB rated generic equivalent to the antianginal drug Imdur®. It is indicated for the prevention of angina pectoris due to coronary artery disease. According to IMS data for the twelve-months ended December 2016, the U.S. market for Isosorbide Mononitrate 30mg ER tablets is approximately $35 million.

Download Press Release